Your browser doesn't support javascript.
loading
Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus.
Rafati, Alireza; Esmaeili Gouvarchin Ghaleh, Hadi; Azarabadi, Afsaneh; Masoudi, Mahmood Reza; Afrasiab, Elmira; Ghorbani Alvanegh, Akbar.
Afiliação
  • Rafati A; Department of Medical Genetics, Sirjan School of Medical Sciences, Sirjan, Iran.
  • Esmaeili Gouvarchin Ghaleh H; Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Azarabadi A; Instructor of Nursing, School of Nursing and Midwifery, Urmia University of Medical Sciences.
  • Masoudi MR; School of Medical Sciences, Emam Reza Hospital Sirjan Faculty of Medical Sciences, Sirjan, Iran.
  • Afrasiab E; Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
  • Ghorbani Alvanegh A; Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran; Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: alvanegh@gmail.com.
Transpl Immunol ; 75: 101721, 2022 12.
Article em En | MEDLINE | ID: mdl-36150664
ABSTRACT
BACKGROUND AND

AIM:

Various chemical drugs have been approved for the treatment of patients with hepatitis C, but most of these treatments are costly, and also have an inadequate response and many side effects. Also, there is no effective vaccine for hepatitis C due to its high genetic diversity. In recent decades, clinical trials have grown dramatically regarding the benefits of stem cell therapy as a modulator of immune system responses and anti-inflammatory drugs. The most promising point in stem cell therapy and similar therapies is that patients with chronic pain and severe injuries are offered drug-free treatment or surgery. In the present study, we examine the various dimensions of the use of stem cells with the approach of gene therapy carriers as a new treatment method in the treatment of Hepatitis C.

METHODS:

Search terms were including gene carrier, stem cell therapy, gene therapy, liver disorders, hepatitis C virus. At first, 1000 article titles related to the mentioned keywords for different diseases were found. After removing duplicate titles and items that did not match the scope of the research, articles that met the criteria for entering the research and had usable information were selected. All abstracts of selected articles were studied by researchers. In the initial review, articles related to the title were identified and categorized based on the type of challenge.

CONCLUSION:

Gene therapy, either directly and in vivo or indirectly and in vitro, requires carriers (vectors) to transfer the gene. These carriers are divided into two groups, viral and non-viral. In indirect gene therapy, living cells are isolated from a person's body and genetically modified. Stem cells have the properties to transfer the desired genes to the patient's body, including the ability to proliferate for a long time and differentiate into the tissue cells in which they are located.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatopatias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C / Hepatopatias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article